{"id":31067,"date":"2020-07-10T09:33:30","date_gmt":"2020-07-10T07:33:30","guid":{"rendered":"https:\/\/fvz.upr.si\/?post_type=project&p=31067"},"modified":"2020-10-26T08:58:13","modified_gmt":"2020-10-26T07:58:13","slug":"j3-8209-bilirubin-as-a-protective-factor-against-the-development-of-chronic-degenerative-diseases-serum-biomarker-and-pharmacological-modulation-basic-project-arrs","status":"publish","type":"project","link":"https:\/\/fvz.upr.si\/en\/project\/j3-8209-bilirubin-as-a-protective-factor-against-the-development-of-chronic-degenerative-diseases-serum-biomarker-and-pharmacological-modulation-basic-project-arrs\/","title":{"rendered":"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS)"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.4.2″ background_enable_color=”off” background_image=”https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg” height=”330px” animation_style=”fade” custom_css_main_element=”padding-top: 0;||padding-bottom: 0;” saved_tabs=”all”][et_pb_row _builder_version=”3.27.2″ height=”100%” custom_css_main_element=”position: relative;||padding-top: 0;||padding-bottom: 0;”][et_pb_column type=”4_4″ _builder_version=”3.27.2″ custom_css_main_element=”height: 100%;”][et_pb_text _builder_version=”3.27.4″ _dynamic_attributes=”content” text_font=”Fira Sans|||on|||||” text_text_color=”#ffffff” text_font_size=”20px” custom_css_main_element=”background-color: #bf2f1a;||display: inline-block;||position: absolute;||bottom: 0;||padding: 16px;” border_width_all=”2px” border_color_all=”#821f22″ border_width_bottom=”0px”]@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”3.27.2″ background_color=”#f1f0ee” custom_padding=”60px||60px||false|false” custom_padding_tablet=”30px||30px||false|false” custom_padding_phone=”” animation_style=”fade” z_index_tablet=”500″ box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px”][et_pb_row _builder_version=”4.0.5″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”|auto|60px|auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]<\/p>\n

Duration of the project:<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.4.2″ custom_padding=”||0px|||”]<\/p>\n

1. 5. 2017 \u2013 30. 4. 2020<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.27.2″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto|30px|auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_margin=”-35px|||||” custom_padding=”||||false|false”]<\/p>\n

Lead partner: <\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.4.8″ custom_padding=”||0px|||”]<\/p>\n

University of Ljubljana, Faculty of Medicine<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.27.2″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto||auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]<\/p>\n

Project p<\/strong>artners:<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.4.8″ custom_padding=”||0px|||”]<\/p>\n

University of Primorska, Faculty of Health Sciences
University of Nova Gorica
University of Ljubljana Faculty of Pharmacy<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.27.2″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto||auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]<\/p>\n

Principal investigator \/ researcher:<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.6.6″ custom_padding=”||0px|||” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

Assist. Prof. Lovro \u017diberna (SICRIS<\/a>, ResearchGate<\/a>)<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.27.2″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto||auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]<\/p>\n

Team<\/strong> at UP FHS:<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.6.6″ custom_padding=”||0px|||” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

Assist. Prof. Ana Petelin (SICRIS<\/a>, ResearchGate<\/a>)
Assoc. Prof. Zala Jenko Pra\u017enikar\u00a0(SICRIS<\/a>, ResearchGate<\/a>)
Assoc. Prof. Mihaela Jurdana (SICRIS<\/a>, ResearchGate<\/a>)
Assoc. Prof. Ma\u0161a \u010cerneli\u010d Bizjak (SICRIS<\/a>, ResearchGate<\/a>)
Assist. Prof. Mojca Stubelj (SICRIS<\/a>, ResearchGate<\/a>)<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.27.2″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto||auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.27.2″][et_pb_text _builder_version=”4.4.2″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]Povezava: <\/strong>[\/et_pb_text][et_pb_text _builder_version=”4.4.2″ custom_padding=”||0px|||”]<\/p>\n

SICRIS<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.0.5″ width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” custom_margin=”30px|auto||auto|false|false” custom_margin_tablet=”0px||0px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding=”||||false|false” locked=”off”][et_pb_column type=”4_4″ _builder_version=”4.0.5″][et_pb_text _builder_version=”4.4.8″ text_font=”Fira Sans|700||on|||||” text_text_color=”#bf2e1b” text_font_size=”22px” header_font=”Arial|||on|||||” header_2_font=”||||||||” header_2_text_align=”left” header_2_font_size=”24px” custom_padding=”||||false|false”]<\/p>\n

Abstract:<\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.4.8″ custom_padding=”||0px|||”]<\/p>\n

Bilirubin is present in various chemical forms in the blood, namely, conjugated with glucuronic acid (direct bilirubin), unconjugated bound to serum albumin (indirect bilirubin) and unconjugated-unbound (free bilirubin). The bioactive form is the free bilirubin, which is not measured routinely in the clinical setting, but has been recently identified to be around 10 nM in serum. Importantly, nanomolar concentrations of bilirubin can protect cells from the 10,000-fold molar excess of oxidants when both substances are added exogenously to cell culture. This remarkable effect has been explained that bilirubin acting as antioxidant, is itself oxidized to biliverdin, and then recycled by biliverdin reductase back to bilirubin. All in all, bilirubin is an endogenous antioxidant with anti\u2011inflammatory and anti-thrombotic activity, and is inversely correlated with disease risk of the cardiovascular system, such as ischemic heart disease, hypertension, diabetes type II, metabolic syndrome, obesity, among others. Importantly, some positive lifestyle modifications, e.g. weight loss or cessation of smoking, lead to higher levels of serum bilirubin. We hypothesise that bilirubin has the potential to be used as a biomarker for cardiovascular pre\u2011disease states and that serum bilirubin levels can be modulated.<\/p>\n

Modulation of serum bilirubin values is possible by either i) lifestyle modifications (reducing consumption of bilirubin due to decreased oxidative stress and decreased inflammation) or ii) pharmacological interventions (increasing serum bilirubin levels by increasing synthesis, decreasing metabolism and elimination, or by replacing it from albumin) , e.g. biliverdin reductase (BVR) induction, heme oxygenase-1 (HO-1) induction, UDP-glucuronosyltransferase (UGT1A1) inhibition, organic anion transporters (OATP) and bilitranslocase (BTL) inhibition, and on the level of interaction with bilirubin-albumin complex in blood serum.<\/p>\n

\"\"<\/p>\n

The authors acknowledge the project\u00a0\u201cJ3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation<\/strong>\u201d<\/strong>\u00a0is finacially supported by the Slovenian Research Agency.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Duration of the project:1. 5. 2017 \u2013 30. 4. 2020Lead partner: University of Ljubljana, Faculty of MedicineProject partners:University of Primorska, Faculty of Health SciencesUniversity of Nova GoricaUniversity of Ljubljana Faculty […]<\/p>\n","protected":false},"author":12,"featured_media":29111,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"project_category":[139,176,178,180,144],"project_tag":[],"class_list":["post-31067","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-dietetics","project_category-functional-foods-completed","project_category-nutrition-for-health-promotion-completed","project_category-nutritional-therapy-completed","project_category-research-and-development-projects-completed"],"yoast_head":"\nJ3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju\" \/>\n<meta property=\"og:description\" content=\"Duration of the project:1. 5. 2017 \u2013 30. 4. 2020Lead partner: University of Ljubljana, Faculty of MedicineProject partners:University of Primorska, Faculty of Health SciencesUniversity of Nova GoricaUniversity of Ljubljana Faculty […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/\" \/>\n<meta property=\"og:site_name\" content=\"Fakulteta za vede o zdravju\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-26T07:58:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"968\" \/>\n\t<meta property=\"og:image:height\" content=\"468\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/\",\"url\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/\",\"name\":\"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fvz.upr.si\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Raziskovanje-in-razvoj.jpg\",\"datePublished\":\"2020-07-10T07:33:30+00:00\",\"dateModified\":\"2020-10-26T07:58:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fvz.upr.si\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Raziskovanje-in-razvoj.jpg\",\"contentUrl\":\"https:\\\/\\\/fvz.upr.si\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Raziskovanje-in-razvoj.jpg\",\"width\":968,\"height\":468},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fvz.upr.si\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\\\/\\\/fvz.upr.si\\\/project\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#website\",\"url\":\"https:\\\/\\\/fvz.upr.si\\\/\",\"name\":\"Fakulteta za vede o zdravju\",\"description\":\"\u017divljenju dodajamo znanje.\",\"publisher\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fvz.upr.si\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#organization\",\"name\":\"Fakulteta za vede o zdravju\",\"url\":\"https:\\\/\\\/fvz.upr.si\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fvz.upr.si\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/UP-FVZ_logo-transparent.png\",\"contentUrl\":\"https:\\\/\\\/fvz.upr.si\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/UP-FVZ_logo-transparent.png\",\"width\":1417,\"height\":792,\"caption\":\"Fakulteta za vede o zdravju\"},\"image\":{\"@id\":\"https:\\\/\\\/fvz.upr.si\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/","og_locale":"en_US","og_type":"article","og_title":"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju","og_description":"Duration of the project:1. 5. 2017 \u2013 30. 4. 2020Lead partner: University of Ljubljana, Faculty of MedicineProject partners:University of Primorska, Faculty of Health SciencesUniversity of Nova GoricaUniversity of Ljubljana Faculty […]","og_url":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/","og_site_name":"Fakulteta za vede o zdravju","article_modified_time":"2020-10-26T07:58:13+00:00","og_image":[{"width":968,"height":468,"url":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/","url":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/","name":"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS) - Fakulteta za vede o zdravju","isPartOf":{"@id":"https:\/\/fvz.upr.si\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/#primaryimage"},"image":{"@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/#primaryimage"},"thumbnailUrl":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg","datePublished":"2020-07-10T07:33:30+00:00","dateModified":"2020-10-26T07:58:13+00:00","breadcrumb":{"@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/#primaryimage","url":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg","contentUrl":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2020\/04\/Raziskovanje-in-razvoj.jpg","width":968,"height":468},{"@type":"BreadcrumbList","@id":"https:\/\/fvz.upr.si\/project\/j3-8209-bilirubin-kot-zascitni-dejavnik-pred-razvojem-kronicnih-degenerativnih-bolezni-serumski-biomarker-in-moznosti-farmakoloske-modulacije-temeljni-projekt-arrs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fvz.upr.si\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/fvz.upr.si\/project\/"},{"@type":"ListItem","position":3,"name":"J3-8209 Bilirubin as a protective factor against the development of chronic degenerative diseases: serum biomarker and pharmacological modulation (Basic project ARRS)"}]},{"@type":"WebSite","@id":"https:\/\/fvz.upr.si\/#website","url":"https:\/\/fvz.upr.si\/","name":"Fakulteta za vede o zdravju","description":"\u017divljenju dodajamo znanje.","publisher":{"@id":"https:\/\/fvz.upr.si\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fvz.upr.si\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fvz.upr.si\/#organization","name":"Fakulteta za vede o zdravju","url":"https:\/\/fvz.upr.si\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fvz.upr.si\/#\/schema\/logo\/image\/","url":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2019\/03\/UP-FVZ_logo-transparent.png","contentUrl":"https:\/\/fvz.upr.si\/wp-content\/uploads\/2019\/03\/UP-FVZ_logo-transparent.png","width":1417,"height":792,"caption":"Fakulteta za vede o zdravju"},"image":{"@id":"https:\/\/fvz.upr.si\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project\/31067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/comments?post=31067"}],"version-history":[{"count":5,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project\/31067\/revisions"}],"predecessor-version":[{"id":33883,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project\/31067\/revisions\/33883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/media\/29111"}],"wp:attachment":[{"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/media?parent=31067"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project_category?post=31067"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/fvz.upr.si\/en\/wp-json\/wp\/v2\/project_tag?post=31067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}